Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetrahydrocannabinol (THC) distillate is a highly refined cannabis extract that has undergone a molecular distillation process to isolate Delta-9-tetrahydrocannabinol from other plant compounds, including terpenes, flavonoids, and other cannabinoids. The production process typically involves initial extraction (e.g., using CO2 or ethanol), winterization to remove lipids and waxes, and fractional distillation under vacuum to achieve high purity, often exceeding 90% THC content. Because the distillation process involves heat, the THC is decarboxylated, making the product orally active without further heating. THC distillate acts as a partial agonist at the Cannabinoid Receptor 1 (CB1), primarily located in the central nervous system, and the Cannabinoid Receptor 2 (CB2), found largely in the immune system. It is utilized for its potent analgesic, antiemetic, and appetite-stimulating properties. While not a single FDA-approved pharmaceutical product like Marinol (dronabinol), THC distillate is a standardized ingredient used in various medical and recreational cannabis products in legal jurisdictions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetrahydrocannabinol distillate.